Conference Report

Clinical Update on the Treatment of Pancreatic Cancer

Source: CCO Independent Conference Coverage of the 2007 Gastrointestinal Cancers Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Update on the Treatment of Pancreatic Cancer

Faculty:
Barbara Burtness, MD Eric Van Cutsem, MD, PhD

CME CREDIT INFORMATION

Release Date: 05/07/07

Expiration Date: 05/06/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the effect of gemcitabine-based combination treatments on measures of efficacy or safety, such as overall and progression-free survival
Describe the association between primary malignancies and increased risk of subsequent hepatocellular cancer
Explain the effect of factors including lymph node involvement and adjuvant radiotherapy on survival in patients with pancreatic cancer

Topics covered include:

Gemcitabine Plus Bevacizumab vs Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: CALGB 80303
Gemcitabine-Based Combination Treatments in Advanced Pancreatic Cancer: Meta-analysis of Randomized Trials
Postoperative Gemcitabine and Oxaliplatin Followed by Chemoradiation in Patients With Resected Pancreatic Cancer
Adjuvant Radiation Therapy in Resected Pancreatic Cancer: Population-Based Survival Analysis
Impact of Lymph Node Count and Examination on Patient Survival in Resected Pancreatic Cancer
Serum CA19-9 Measurements vs Objective Radiographic Response as a Predictor of Clinical Outcomes in Patients With Metastatic Pancreatic Cancer
Capecitabine and Oxaliplatin in Patients With Metastatic or Unresectable Adenocarcinoma of the Small Bowel or Ampulla of Vater
Hepatocellular Carcinoma Risk in Patients With a Previous Malignancy

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.